Rockwell Medical (RMTI) Amortization of Deferred Charges (2013 - 2026)
Rockwell Medical (RMTI) posted Amortization of Deferred Charges of $88000.0 for Q1 2026, down 1.12% on a QoQ basis from $89000.0 in Q4 2025, and little changed year-over-year from $88000.0 in Q1 2025.
Rockwell Medical (RMTI) Amortization of Deferred Charges (2013 - 2026) Analysis & Trends
Rockwell Medical's Amortization of Deferred Charges history runs 9 years deep, the most recent figure standing at $88000.0 for Q1 2026.
- Quarterly Amortization of Deferred Charges changed 0.0% year-over-year to $88000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $354000.0 (up 20.0% YoY) and the FY2025 annual result came in at $354000.0, down 16.9% from the prior year.
- Amortization of Deferred Charges was $88000.0 for Q1 2026 at Rockwell Medical, down from $89000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $831000.0 in Q4 2023 and bottomed at $30000.0 in Q2 2024.
- A 5-year average of $137882.4 and a median of $92000.0 in 2022 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2022 — Amortization of Deferred Charges sank 94.08% — and 2023, when it jumped 793.55%.
- Rockwell Medical's Amortization of Deferred Charges stood at $93000.0 in 2022, then soared by 793.55% to $831000.0 in 2023, then sank by 89.29% to $89000.0 in 2024, then changed by 0.0% to $89000.0 in 2025, then retreated by 1.12% to $88000.0 in 2026.
- Business Quant data shows RMTI's Amortization of Deferred Charges at $88000.0 in Q1 2026, $89000.0 in Q4 2025, and $89000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.51 Bn | 87.64 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.95 Bn | 32.21 Bn | 1.97 Bn |
| 3 | Zoetis | 32.59 Bn | 30.65 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.51 Bn | 23.45 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.06 Bn | 20.91 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - |
| 7 | Viatris | 20.25 Bn | 18.44 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.48 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Rockwell Medical | 28.34 Mn | 4.45 Mn | 2.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 88,000.00 |
| Mar 31, 2026 | 88,000.00 |
| Dec 31, 2025 | 89,000.00 |
| Dec 31, 2025 | 89,000.00 |
| Sep 30, 2025 | 89,000.00 |
| Sep 30, 2025 | 89,000.00 |
| Jun 30, 2025 | 88,000.00 |
| Jun 30, 2025 | 88,000.00 |
| Mar 31, 2025 | 88,000.00 |
| Mar 31, 2025 | 88,000.00 |
| Dec 31, 2024 | 89,000.00 |
| Dec 31, 2024 | 89,000.00 |
| Sep 30, 2024 | 88,000.00 |
| Sep 30, 2024 | 88,000.00 |
| Jun 30, 2024 | 30,000.00 |
| Jun 30, 2024 | 30,000.00 |
| Mar 31, 2024 | 219,000.00 |
| Mar 31, 2024 | 219,000.00 |
| Dec 31, 2023 | 831,000.00 |
| Dec 31, 2023 | 831,000.00 |